Amgen Inc. vs Bio-Techne Corporation: SG&A Expense Trends

SG&A Expense Trends: Amgen Inc. vs Bio-Techne Corporation

In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two industry giants: Amgen Inc. and Bio-Techne Corporation, from 2014 to 2023.

Amgen Inc., a leader in the biotech sector, has seen its SG&A expenses grow by approximately 31% over the decade, peaking in 2023. This reflects strategic investments in marketing and administration to maintain its market dominance. In contrast, Bio-Techne Corporation, while smaller, has demonstrated a remarkable 522% increase in SG&A expenses, indicating aggressive expansion and scaling efforts.

The data reveals a consistent upward trend for both companies, with Amgen's expenses significantly higher, reflecting its larger scale. However, Bio-Techne's rapid growth in expenses suggests a dynamic shift in its operational strategy, potentially positioning it for future market challenges.